Bayer's impact investment arm returned for the round's $45m second close, as Triumvera looks to progess its solid tumour therapeutic candidate.
Leaps by Bayer, the impact corporate venturing arm of pharmaceutical and chemicals group Bayer, helped US-headquartered cancer therapeutics developer Triumvira Immunologics expand its series A round to $100m yesterday.
The $45m extension also featured Multiple Myeloma Research Foundation’s venture philanthropy subsidiary as well as B Capital Group, Atem Capital, Myeloma Investment Fund, Northpond Ventures and undisclosed other investors.
Triumvira is working on non-gene edited autologous and allogeneic T cell medications designed to leverage the biology of T cells to treat…
